The effect of direct-acting antivirals (DAA) on confirmed noninvasive fibrous parameters in chronic hepatitis C patients

Abstract

Aims: Chronic hepatitis C (CHC) is an important public health problem in terms of the number of people it affects worldwide and the diseases it causes. The high sustained virological response (SVR) rates achieved by the use of direct-acting antiviral (DAA) drugs in the recent period have shown that a new era has begun in this disease. It was aimed to evaluate the effect of DAAs on confirmed noninvasive fibrous parameters together with their effectiveness.
 Methods: 75 patients who were started on DAA treatment for CHC were included in the study. In addition, laboratory parameters values at the beginning of the treatment, 12 and 24 weeks after the end of the treatment, hepatitis C virus ribonucleic acid (HCV RNA) results and Aminotransferase-to-Platelet Ratio Index (APRI), Fibrosis-4 (FIB-4) scores were compared.
 Results: The most common comorbidity in patients is hypertension (HT), and the most common source of transmission is surgical operations. Genotype 1b was the dominant genotype. The SVR rates of all patients 12 and 24 weeks after the end of treatment were 100%. The APRI and FIB-4 scores of the patients decreased significantly at the 12th and 24th weeks at the end of the treatment compared to the beginning of the treatment.
 Conclusion: The confirmed noninvasive fibrous parameters used in the treatment of CHC are useful in evaluating the results of the treatments applied.